Clinical trials: TCC
Urologic Neoplasms, Carcinoma, Transitional Cell
2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen
To investigate efficacy and safety of 2nd line GEM monotherapy after CDDP regimen for patients with transitional cell carcinoma of urothelium
- Trial name
- NCT00191971
- Testing
- Gemcitabine
- Where
- 12 sites in Japan
- Volunteers
- 40 people
- Sponsor
- Eli Lilly and Company
TCC
Perioperative Intravesical Instilation of Hypertonic Saline Following Bladder Tumor Resection
Hypertonic saline at the concentration of 3% (hypersel) has been injected for years into echinococcal cysts to kill live scolices, and is also known to kill suspended cells by means of a steep osmotic gradient and the…
- Trial name
- NCT04147182
- Testing
- Hypertonic Saline 3%
- Where
- Israel
- Volunteers
- 15 people
- Sponsor
- Dan Leibovici
Transitional Cell Carcinoma
Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint Inhibitor
This study is designed to evaluate response and survival of treatment with the combination of pembrolizumab and ramucirumab in patients with progressive metastatic TCC after immune checkpoint inhibitor treatment.
- Trial name
- NCT04179110
- Testing
- Pembrolizumab and Ramucirumab
- Where
- United States
- Sponsor
- Yale University
Diabetic Foot Ulcers, Diabetes
A Comparison of TCC-EZ Using Human Amnion Allograft vs TCC-EZ and Standard Wound Care in Treating Diabetic Foot Ulcers.
A Comparison of AmnioExcel® and Total Contact Casting (TCC-EZ) Versus Standard Wound Care and TCC-EZ in Treating Diabetic Foot Ulcers Best practice is to treat DFUs with standardized care and, if unsuccessful, use advanced…
- Trial name
- TAD (NCT02344329)
- Testing
- Topical wound dressing, Human Amnion Allograft, usual wound care
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of North Dakota
Carcinoma Transitional Cell
Study of BEZ235 as Monotherapy in Patients With Transitional Cell Carcinoma After Failure of Platinum Based Chemotherapy
The mTOR (mammalian Target of Rapamycin) protein is the center of the mTOR pathway that plays an important role in cell growth, proliferation, survival and angiogenesis through sensing and integrating energetic signals from…
- Trial name
- BEZ235 (NCT01856101)
- Testing
- BEZ235
- Where
- 12 sites in Belgium, Luxembourg
- Volunteers
- 22 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
End Stage Renal Disease, Hemodialysis
Addition of Heparin to Taurolock-TM CLS in HD Patients With TCC Dose it Improve Catheter Patency Problems ?
Addition of Heparin to the Catheter Lock Solution (CLS): Taurolock-TM will improve the vascular patency compared to Taurolock-TM alone , in hemodialysis patients with Tunneled Cuffed Catheter(TCC) as vascular access.
- Trial name
- NCT00749619
- Testing
- Catheter Lock Solution Taurolidine and Citrate, Catheter Lock Solution :Taurolidine and Citrate and Heparin, Catheter Lock Solution : Heparin
- Where
- Israel
- Sponsor
- Western Galilee Hospital-Nahariya
Transitional Cell Carcinoma
A Single Arm, Multicenter, Phase II Trial of RAD001 as Monotherapy in the Palliative Treatment of Patients With TCC After Failure of Chemotherapy
An open-label, single arm, non-randomized, single stage phase II study. 3 phases:Baseline, treatment/duration and Follow-up. All patients will be treated with RAD001 10 mg daily dose until disease progression or unacceptable…
- Trial name
- NCT00714025
- Testing
- RAD001
- Where
- Belgium
- Volunteers
- 40 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Transitional Cell Carcinoma, Renal Cell Cancer
Relationship of Ochratoxin A to Upper Urologic Cancers
This pilot study will explore the relationship of Ochratoxin A (OTA) levels in patients with upper tract transitional cell (TCC), renal cell, and testicular cancers by measuring levels of OTA in serum and tumor samples.
- Conditions
- Transitional Cell Carcinoma, Renal Cell Cancer, Testicular Cancer
- Trial name
- NCT00216801
- Where
- Canada
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Depression - Major Depressive Disorder, Insomnia
Combined Effect of TCC-I and BATD on Depressive Symptoms and Insomnia
The goals of this interventional study is to study if the combine effects of Behavioral Activation Treatment for Depression (BATD) and Cognitive Behavioral Therapy for Insomnia (CBT-I) is effective on primary outcomes …
- Trial name
- NCT06633263
- Testing
- Cognitive Behavioral Therapy for Insomnia, Behavioral Activation Treatment for Depression
- Where
- Belgium
- Volunteers
- 12 people
- Sponsor
- University of Liege
Dry Age-related Macular Degeneration
Treatment of Advanced Dry Age Related Macular Degeneration With AAVCAGsCD59
Age related macular degeneration (AMD) is the leading cause of vision loss in individuals over age 60. AMD is classified as wet and dry.
- Trial name
- NCT03144999
- Testing
- AAVCAGsCD59
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Janssen Research & Development, LLC
Transitional Cell Carcinoma
Weekly TP-HDFL in the Treatment of Advanced TCC
The purpose of this study is to evaluate the efficacy of Weekly TP-HDFL in advanced transitional cell carcinoma in terms of response rate and overall survival.
- Trial name
- NCT00154687
- Testing
- Paclitaxel, Cisplatin, 5-Fluorouracil
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- National Taiwan University Hospital
Bladder Cancer
A Double Blind Randomised Study of Lapatinib and Placebo in Metastatic TCC of the Urothelium
RATIONALE: Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether lapatinib ditosylate is more effective than a placebo in killing tumor cells.
- Trial name
- LaMB (NCT00949455)
- Testing
- lapatinib ditosylate
- Where
- 27 sites in United Kingdom
- Volunteers
- 204 people
- Sponsor
- Queen Mary University of London
Glomerulonephritis, Membranous
Efficacy and Safety Study of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy
The main clinical study will be a randomized, double-blind, placebo-controlled, long term study involving a 100 week treatment period.
- Trial name
- NCT01762852
- Testing
- Belimumab 10 mg
- Where
- 30 sites in United States, Australia and 8 more
- Sponsor
- GlaxoSmithKline